- Email: [email protected]
5589574 Assay for bone alkaline phosphatase
PATENT ABSTRACTS
773
5589483
5591427
ISOQUINOLINE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT SKIN DISEASES ASSOCIATED WITH CELLULAR SENESCENCE
HUMAN INTERLEUKIN-3(IL-3) VARIANTS AND THEIR USE TO PROMOTE OR ANTAGONIZE IL-3-MEDIATED PROCESSES
West Michael Belmont, CA, UNITED STATES Assigned to Geron Corporation Inhibition of the enzyme poly (ADP-ribose) polymerase can delay the onset of senescence and inhibitors of the enzyme can be used to treat diseases caused or exacerbated by cellular senescence.
5589572 PROCESS FOR PRODUCTION OF INHIBITED FORMS OF ACTIVATED BLOOD FACTORS
Vadas Mathew A; Lopez Angel F; Shannon Mary F South Australia, AUSTRALIA Assigned to Medvet Science Pty Ltd PCT No. PCT/AU92/00535 Sec. 371 Date Jun. 20, 1994 Sec. 102(e) Date Jun. 20, 1994 PCT Filed Oct. 7, 1992 PCT Pub. No. WO93/07171 PCT Pub. Date Apr. 15, 1993. This invention relates to human IL-3 variants. The human IL-3 variants are used in pharmaceutical compositions, in methods for modulating proliferation, differentiation or functional activation of cells expressing the IL-3 receptor, and in methods of treatment.
King Robert Fremont, CA, UNITED STATES Assigned to COR Therapeutics Inc A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.
5589574 ASSAY FOR BONE ALKALINE PHOSPHATASE Wolfert Robert L; Hill Craig San Diego, CA, UNITED STATES Assigned to Hybritech Incorporated Monoclonal antibodies highly specific for human bone alkaline phosphatase, especially in the presence of human liver alkaline phosphatase, and their use in assays for human bone alkaline phosphatase are disclosed. A kit using the antibodies in an assay for human bone alkaline phosphatase is also disclosed.
5591430 ISOLATED, MAGE-3 DERIVED PEPTIDES WHICH COMPLEX WITH HLA-A2 MOLECULES AND USES THEREOF Townsend Alan; Bastin Judy; Boon-Faileur Thierry; van der Bruggen Pierre; Coulie Pierre; Gajewski Thomas Headington, UNITED KINGDOM Assigned to Ludwig Institute for Cancer Research; The Chancellor Masters and Scholars of the University of Oxford Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These TRAS bind to the MHC-class I molecule HLA-A2,and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
773
5589483
5591427
ISOQUINOLINE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT SKIN DISEASES ASSOCIATED WITH CELLULAR SENESCENCE
HUMAN INTERLEUKIN-3(IL-3) VARIANTS AND THEIR USE TO PROMOTE OR ANTAGONIZE IL-3-MEDIATED PROCESSES
West Michael Belmont, CA, UNITED STATES Assigned to Geron Corporation Inhibition of the enzyme poly (ADP-ribose) polymerase can delay the onset of senescence and inhibitors of the enzyme can be used to treat diseases caused or exacerbated by cellular senescence.
5589572 PROCESS FOR PRODUCTION OF INHIBITED FORMS OF ACTIVATED BLOOD FACTORS
Vadas Mathew A; Lopez Angel F; Shannon Mary F South Australia, AUSTRALIA Assigned to Medvet Science Pty Ltd PCT No. PCT/AU92/00535 Sec. 371 Date Jun. 20, 1994 Sec. 102(e) Date Jun. 20, 1994 PCT Filed Oct. 7, 1992 PCT Pub. No. WO93/07171 PCT Pub. Date Apr. 15, 1993. This invention relates to human IL-3 variants. The human IL-3 variants are used in pharmaceutical compositions, in methods for modulating proliferation, differentiation or functional activation of cells expressing the IL-3 receptor, and in methods of treatment.
King Robert Fremont, CA, UNITED STATES Assigned to COR Therapeutics Inc A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.
5589574 ASSAY FOR BONE ALKALINE PHOSPHATASE Wolfert Robert L; Hill Craig San Diego, CA, UNITED STATES Assigned to Hybritech Incorporated Monoclonal antibodies highly specific for human bone alkaline phosphatase, especially in the presence of human liver alkaline phosphatase, and their use in assays for human bone alkaline phosphatase are disclosed. A kit using the antibodies in an assay for human bone alkaline phosphatase is also disclosed.
5591430 ISOLATED, MAGE-3 DERIVED PEPTIDES WHICH COMPLEX WITH HLA-A2 MOLECULES AND USES THEREOF Townsend Alan; Bastin Judy; Boon-Faileur Thierry; van der Bruggen Pierre; Coulie Pierre; Gajewski Thomas Headington, UNITED KINGDOM Assigned to Ludwig Institute for Cancer Research; The Chancellor Masters and Scholars of the University of Oxford Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These TRAS bind to the MHC-class I molecule HLA-A2,and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.